Monopar Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MNPR research report →
Range $105 – $133
Price Chart
About the company
Monopar Therapeutics Inc. , a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
- CEO
- Chandler D. Robinson
- IPO
- 2019
- Employees
- 22
- HQ
- Wilmette, IL, US
Get TickerSpark's AI analysis on MNPR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $760.38M
- P/E
- -48.51
- Fwd P/E
- 181.40
- PEG
- 1.70
- P/S
- 0.00
- P/B
- 7.41
- EV/EBITDA
- -38.26
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -13.08%
- ROIC
- -16.89%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-16,704,415
- Net Income
- $-13,716,894+12.0%
- EPS
- $-1.85-36.0%
- OCF Growth
- -90.5%
- FCF Growth
- -90.5%
- 52W High
- $124.82
- 52W Low
- $29.18
- 50D MA
- $98.76
- 200D MA
- $73.24
- Beta
- 1.51
- RSI (14)
- 54
- Avg Volume
- 239.75K
No earnings-call transcripts are available for MNPR yet.
- Free Float
- 62.1%
- Shares Outstanding
- 6.70M
- Float Shares
- 4.16M
of shares held by institutions
73 13F filers
Buy/sell ratio 0.67. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Janus Henderson Group PLC | 1.32M | 0 |
| Vanguard Group Inc | 293.82K | ▲ 85.60K |
| Quest Partners LLC | 1.98K | ▲ 48 |
| California State Teachers Retirement System | 247 | ▼ 34 |
| Cwm, LLC | 15 | ▲ 15 |
Held by 95 ETFs
Biggest fund positions in MNPR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 26 | Vu Quan Anh | other | 1,228 |
| Jun 30, 26 | Vu Quan Anh | other | 1,228 |
| Jun 30, 26 | Vu Quan Anh | other | 507 |
| Jun 30, 26 | Robinson Chandler | other | 12,873 |
| Jun 30, 26 | Robinson Chandler | other | 4,084 |
| Jun 30, 26 | Robinson Chandler | other | 12,873 |
| Jun 30, 26 | Cittadine Andrew | other | 5,254 |
| Jun 30, 26 | Cittadine Andrew | other | 2,309 |
| Jun 30, 26 | Cittadine Andrew | other | 5,254 |
| Jun 26, 26 | Sweeny Nicole | other | 1,284 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MNPR coverage
Recent articles, reports, and earnings notes.
No research on MNPR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MNPR report →Monopar Appoints Jeffrey D. Kent, M.D.
globenewswire.com · Aug 19
Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy'
seekingalpha.com · Aug 18
Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More
247wallst.com · Aug 13
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
globenewswire.com · Aug 12
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
globenewswire.com · Jul 22
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
globenewswire.com · Jul 20
Monopar Therapeutics: ALXN1840's Bull Case Has Improved
seekingalpha.com · Jul 3
Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
globenewswire.com · Jun 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.